Printed from Voxsanity (voxsanity.com.au) — NCT06782490 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
You have been diagnosed with multiple sclerosis (MS).
You have had muscle stiffness or spasms (called spasticity) caused by MS for at least 6 months before your first study visit.
At your first study visit, you have a certain level of muscle stiffness (measured by a standard scale called the Modified Ashworth Scale) in at least 2 muscle groups, with at least one of those groups being in your leg (not including the ankle) (confirm with trial site).
At your first study visit, your level of MS-related disability falls within a specific range on a standard scale called the Expanded Disability Status Scale (EDSS), roughly covering moderate to moderately severe disability (confirm with trial site).
Who may not be able to join:
You have another condition or illness that also causes muscle stiffness or spasms, or that could affect your level of spasticity.
You have had an MS relapse or flare-up needing treatment, or a change in your MS medication dose, within 3 months before your first or second study visit.
You have a history of a substance use disorder involving drugs or alcohol, as defined by standard medical guidelines.
You are currently taking a medication for spasticity that cannot be stopped and cleared from your system before your second study visit.
You have used any cannabis-related products — including cannabis, CBD, or THC — or certain related medications (called FAAH/MAGL inhibitors) in the 30 days before your first study visit.
There may be additional eligibility requirements not listed here (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
John Hunter Hospital, Newcastle, New South Wales
+61 2 4042 0682
University of Sydney - Brain and Mind Research Institute (BMRI), Sydney, New South Wales
+61 2 9351 0704
Centre for Neuroscience Innovation, Kent Town, South Australia
+61 8 81320494
Box Hill Hospital, Box Hill, Victoria
+61 3 9094 9527
Austin Health, Heidelberg, Victoria
+61 3 94963705
The Royal Melbourne Hospital, Parkville, Victoria
+ 61 3 93429092
Perron Institute, Nedlands, Western Australia
+61 8 6457 0213
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT06782490
Sponsor: Celgene
Phase: Phase 2
Status: Recruiting
Condition: Multiple Sclerosis
Trial contact: 855-907-3286
More information: https://clinicaltrials.gov/study/NCT06782490
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
You have been diagnosed with multiple sclerosis (MS).
You have had muscle stiffness or spasms (called spasticity) caused by MS for at least 6 months before your first study visit.
At your first study visit, you have a certain level of muscle stiffness (measured by a standard scale called the Modified Ashworth Scale) in at least 2 muscle groups, with at least one of those groups being in your leg (not including the ankle) (confirm with trial site).
At your first study visit, your level of MS-related disability falls within a specific range on a standard scale called the Expanded Disability Status Scale (EDSS), roughly covering moderate to moderately severe disability (confirm with trial site).
Who may not be able to join:
You have another condition or illness that also causes muscle stiffness or spasms, or that could affect your level of spasticity.
You have had an MS relapse or flare-up needing treatment, or a change in your MS medication dose, within 3 months before your first or second study visit.
You have a history of a substance use disorder involving drugs or alcohol, as defined by standard medical guidelines.
You are currently taking a medication for spasticity that cannot be stopped and cleared from your system before your second study visit.
You have used any cannabis-related products — including cannabis, CBD, or THC — or certain related medications (called FAAH/MAGL inhibitors) in the 30 days before your first study visit.
There may be additional eligibility requirements not listed here (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Phase 2
Sponsor
Celgene
Registry
ClinicalTrials.gov
Start date
5 June 2025
Est. completion
26 May 2027
Where this trial is recruiting
🇦🇺 Australia
🇨🇦 Canada
🇨🇿 Czechia
🇩🇪 Germany
🇵🇱 Poland
Puerto Rico
🇺🇸 United States
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change from baseline in Total Numeric-transformed Modified Ashworth Scale-Most Affected Lower Limb (TNmAS-MALL) score
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.